Furthermore, KC was found to have a central role in the pathophysiological process of peripheral neuropathy also evident by a reduction in neuropathic pain upon pharmacological blockade of KC receptor- CXCR2 by the selective antagonist (Manjavachi et al., 2014; Piotrowska et al., 2019). The gene discussed is CXCR2; the disease is peripheral neuropathy.